Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis

Abstract

Here, we describe the surprising residual capability of the Rb pathway to negatively regulate proliferation and tumorigenesis in a SV40 large T antigen (Tag)-driven mouse model of pancreatic islet carcinogenesis. Heterogeneous Tag expression during all progression stages suggested that a threshold level of the T antigen oncoprotein might be deterministic for β-cell hyperproliferation and led us to hypothesize that Tag might not be fully inhibiting the tumor suppressor activity of Rb. Moreover, genomic profiling of these tumors by array CGH pointed to regions of loss on chromosomes 6 and 14, where the Rb pathway inhibitor p27 and Rb itself, respectively, reside. Indeed, genetic ablation of the p27Kip1 or Rb genes accentuated Tag-induced tumorigenesis, with loss of Rb in particular broadly enhancing multiple parameters of tumorigenesis including the frequency and growth rates of premalignant lesions, of nascent solid tumors, and of invasive carcinomas. The data indicate that attenuation rather than complete inactivation of Rb tumor suppressor gene function, in the context of p53 inhibition, is sufficient to initiate tumorigenesis in this model of islet cell cancer, with the demonstrable possibility that subsequent losses of Rb or its regulators can enhance malignant progression. The results may be relevant to human papillomavirus (HPV)-induced cervical neoplasias where E7 oncogene expression levels or activity (in the case of intermediate/low-risk HPV subtypes) incompletely inhibits Rb tumor suppressor functions, as well as to other neoplasias where initiating oncogenic or tumor suppressor events reduce but do not abrogate Rb function.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Bader JL, Miller RW, Meadows AT, Zimmerman LE, Champion LA and Voute PA . (1980). Lancet, 2, 582–583.

  • Bergers G, Song S, Meyer-Morse N, Bergsland E and Hanahan D . (2003). J. Clin. Invest., 111, 1287–1295.

  • Brownstein S, de Chadarevian JP and Little JM . (1984). Arch. Ophthalmol., 102, 257–262.

  • Christofori G, Naik P and Hanahan D . (1994). Nature, 369, 414–418.

  • Efrat S, Baekkeskov S, Lane D and Hanahan D . (1987). EMBO J., 6, 2699–2704.

  • Ferguson KL, Vanderluit JL, Hebert JM, McIntosh WC, Tibbo E, MacLaurin JG, Park DS, Wallace VA, Vooijs M, McConnell SK and Slack RS . (2002). EMBO J., 21, 3337–3346.

  • Gannon M, Shiota C, Postic C, Wright CV and Magnuson M . (2000). Genesis, 26, 139–142.

  • Giannoudis A and Herrington CS . (2000). Cancer, 89, 1300–1307.

  • Hager JH, Hodgson JG, Fridlyand J, Hariono S, Gray JW and Hanahan D . (2004). Cancer Res., 64, 2406–2410.

  • Hanahan D . (1985). Nature, 315, 115–122.

  • Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK and McDonald DM . (2000). Am. J. Pathol., 156, 1363–1380.

  • Herzig M, Novatchkova M and Christofori G . (1999). Biol. Chem., 380, 203–211.

  • Hodgson G, Hager JH, Volik S, Hariono S, Wernick M, Moore D, Nowak N, Albertson DG, Pinkel D, Collins C, Hanahan D and Gray JW . (2001). Nat. Genet., 29, 459–464.

  • Inoue M, Hager JH, Ferrara N, Gerber HP and Hanahan D . (2002). Cancer Cell, 1, 193–202.

  • Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA and Weinberg RA . (1992). Nature, 359, 295–300.

  • Kim HJ, Song ES and Hwang TS . (2001). Eur. J. Obstet. Gynecol. Reprod. Biol., 98, 213–218.

  • Lo KW, Mok CH, Chung G, Huang DP, Wong F, Chan M, Lee JC and Tsao SW . (1992). Anticancer Res., 12, 1989–1994.

  • Lopez T and Hanahan D . (2002). Cancer Cell, 1, 339–353.

  • Marino S, Vooijs M, van Der Gulden H, Jonkers J and Berns A . (2000). Genes Dev., 14, 994–1004.

  • Nakagawa S, Yoshikawa H, Jimbo H, Onda T, Yasugi T, Matsumoto K, Kino N, Kawana K, Kozuka T, Nakagawa K, Aoki M and Taketani Y . (1999). Br. J. Cancer, 79, 1139–1144.

  • Peters MG, Vidal Mdel C, Gimenez L, Mauro L, Armanasco E, Cresta C, Bal de Kier Joffe E and Puricelli L . (2004). Oncol. Rep., 12, 1143–1150.

  • Pipas JM and Levine AJ . (2001). Semin. Cancer Biol., 11, 23–30.

  • Pipeleers DG . (1992). Diabetes, 41, 777–781.

  • Saenz-Robles MT, Sullivan CS and Pipas JM . (2001). Oncogene, 20, 7899–7907.

  • Sang BC and Barbosa MS . (1992). Proc. Natl. Acad. Sci. USA, 89, 8063–8067.

  • Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S and Sharma A . (2001). Diabetes, 50 (Suppl 1), S154–S159.

Download references

Acknowledgements

We wish to thank Mark Magnuson (Vanderbilt University, Nashville, TN, USA) for providing us the RIP2-Cre transgenic mice and Anton Berns (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for the Rb-floxed allele animals, and Cherry Concengo, Marina Vayner, Susan Cacacho and Ehud Drori for excellent technical support. This research was supported by grants from the US National Cancer Institute. DH is an American Cancer Society Research Professor, and thanks the ACS for their support.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Douglas Hanahan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Casanovas, O., Hager, J., Chun, M. et al. Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis. Oncogene 24, 6597–6604 (2005). https://doi.org/10.1038/sj.onc.1208823

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208823

Keywords

This article is cited by

Search

Quick links